What is a common adverse reaction associated with adrenocortical carcinoma medications like mitotane?

What is a common adverse reaction associated with adrenocortical carcinoma medications like mitotane?

• A. Weight gain
• B. Edema
• C. Dry skin
• D. Vision changes

Answer: (B)

Mitotane is a medication used in the treatment of adrenocortical carcinoma, a type of cancer affecting the adrenal glands. One of the common adverse reactions associated with mitotane and similar adrenocortical agents is edema, which is the accumulation of fluid in body tissues leading to swelling. This side effect can occur due to the medication's impact on adrenal hormone production and the body's regulation of fluid balance. While the other choices might seem plausible, they are less directly tied to the effects of adrenocortical carcinoma medications. For example, weight gain can be a result of other factors, including hormonal changes unrelated to mitotane. Dry skin and vision changes are also not typical adverse effects of this drug. In contrast, edema is recognized as a specific adverse reaction of concern that may warrant monitoring and management during treatment, making it the correct answer in this context.

Mitotane is a medication used in the treatment of adrenocortical carcinoma, a type of cancer affecting the adrenal glands. One of the common adverse reactions associated with mitotane and similar adrenocortical agents is edema, which is the accumulation of fluid in body tissues leading to swelling. This side effect can occur due to the medication's impact on adrenal hormone production and the body's regulation of fluid balance.

While the other choices might seem plausible, they are less directly tied to the effects of adrenocortical carcinoma medications. For example, weight gain can be a result of other factors, including hormonal changes unrelated to mitotane. Dry skin and vision changes are also not typical adverse effects of this drug. In contrast, edema is recognized as a specific adverse reaction of concern that may warrant monitoring and management during treatment, making it the correct answer in this context.